Biotech Catalysts to Watch: Key Developments for Q4 2026

As 2026 winds down, several biotech catalysts could significantly sway stock valuations in the sector. We spotlight seven pivotal developments with varying approval probabilities, each offering insights into their respective fields. Our focus is on the upcoming milestones, particularly the dates and mechanisms that might drive market shifts.

The full biotech catalysts to watch

TNX-103: A Potential Breakthrough for PH-HFpEF

Tenax Therapeutics (TENX) faces a critical moment on August 29, 2026, when it will unveil results from the Phase 3 trial of TNX-103 (oral levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The estimated probability of approval (PoA) is 38%. This reflects both the urgency of this unmet medical need and the robust trial design. TNX-103 targets a significant market valued at $8.5 billion, given the limited current treatment options. The Phase 3 program includes two pivotal trials, LEVEL and LEVEL-2, aimed at enhancing exercise capacity. Interim results from LEVEL have shown promising safety data, but the absence of disclosed efficacy data fuels skepticism. The standard deviation in six-minute walk distance (6MWD) change being below the expected 55 meters raises concerns about the trial's sensitivity to placebo effects. If successful, TNX-103 could establish itself as a first-in-class treatment, though the lack of Fast Track or Breakthrough Therapy designations adds risk. Investors should brace for volatility around the August 29 readout.

SION-451: Early Stage Risks in Cystic Fibrosis Development

Sionna Therapeutics (SION) plans to report data from its Phase 1 trial of SION-451 on August 31, 2026. This first-in-class nucleotide binding domain 1 (NBD1) stabilizer is being tested in healthy volunteers, yet the lack of a therapeutic indication poses challenges. The estimated PoA is just 18%, primarily because the trial focuses on safety and pharmacokinetics rather than efficacy. The market for this indication is effectively $0, as it targets healthy individuals instead of patients. While the trial aims to explore tolerability in combination with proprietary CFTR correctors, the absence of efficacy data in cystic fibrosis patients clouds the investment outlook. Upcoming catalysts include the topline Phase 1 data, but the timeline remains unclear. Investors should weigh the potential of SION-451 against historical challenges faced by cystic fibrosis therapies.

Foralumab: Challenges in na-SPMS

Tiziana Life Sciences (TLSA) anticipates results from its Phase 2a trial of intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS) in October 2026. The PoA for foralumab is estimated at 20%, reflecting both preliminary positive data and the inherent challenges of the indication. The trial has shown encouraging signs, including stabilization of Expanded Disability Status Scale (EDSS) scores in patients. However, the absence of established regulatory designations and the lack of pivotal efficacy data create considerable uncertainty. The complexities of na-SPMS, characterized by progression independent of relapse, add layers of risk. Investors should remain cautious; while preliminary biomarker signals are promising, the absence of robust efficacy endpoints could hinder approval chances.

Annamycin: A Dual Catalyst in AML Treatment

Marble Arch Pharmaceuticals (MBRX) is preparing for two significant readouts in September 2026 for Annamycin (naxtarubicin), targeting relapsed or refractory acute myeloid leukemia (R/R AML) and second-line AML. Both catalysts are critical, but the PoA remains low, reflecting the challenges in this competitive landscape. The market for AML treatments is substantial, yet Annamycin must compete against established therapies. Investors should be aware that even if the trials yield positive results, the path to FDA approval is fraught with regulatory hurdles. The upcoming data will be pivotal in determining whether Annamycin can carve out a niche in this crowded space.

INO-3107: High Hopes for RRP Treatment

Inovio Pharmaceuticals (INO) is on track to provide data for INO-3107, targeting recurrent respiratory papillomatosis (RRP) on October 30, 2026. This indication has seen limited treatment options historically, making INO-3107's potential particularly noteworthy. The PoA is categorized as high, indicating strong expectations surrounding its efficacy and safety. Given the unmet need in RRP, the anticipated data could generate significant interest. Investors should monitor this catalyst closely, as positive results could position INO-3107 as a leading option for this condition, potentially transforming the patient management landscape.

The bottom line

Monitoring these biotech catalysts is crucial for making informed investment decisions as 2026 comes to a close.